Drugs / VE800
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04208958 | Jan 2020 → Aug 2021 | colorectal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, melanoma +1 | Vedanta Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VE800 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04208958 ↗ |
| Modality | Other / unclassified | “live biotherapeutic product (LBP)” NCT04208958 ↗ |
| Route | Oral | “VE800 is an orally administered (PO) live biotherapeutic product (LBP)” NCT04208958 ↗ |